Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Health disparities

Evidence-based clinical care and policy making for schizophrenia

Nature Reviews Neurology volume 19, pages 643–644 (2023)Cite this article

Subjects

Two recent studies leverage the same French population-based disease registry to describe real-world medication prescription patterns, patient characteristics and treatment effectiveness in people with schizophrenia. These studies also identify disparities in the health care and outcomes of these individuals compared with those of the general population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Taipale, H. et al. Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials. JAMA Psychiatry 79, 210–218 (2022).

    Article  PubMed  Google Scholar 

  2. Fond, G. et al. How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients. Mol. Psychiatry https://doi.org/10.1038/s41380-023-02154-4 (2023).

    Article  PubMed  Google Scholar 

  3. Boyer, L. et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol. Psychiatry https://doi.org/10.1038/s41380-023-02175-z (2023).

    Article  PubMed  Google Scholar 

  4. Solmi, M. et al. Disparities in screening and treatment of cardiovascular diseases in patients with mental disorders across the world: systematic review and meta-analysis of 47 observational studies. Am. J. Psychiatry 178, 793–803 (2021).

    Article  PubMed  Google Scholar 

  5. Wootten, J. C., Wiener, J. C., Blanchette, P. S. & Anderson, K. K. Cancer incidence and stage at diagnosis among people with psychotic disorders: systematic review and meta-analysis. Cancer Epidemiol. 80, 102233 (2022).

    Article  PubMed  Google Scholar 

  6. Correll, C. U. et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry 21, 248–271 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rubio, J. M. et al. Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr. Bull. 47, 1611–1620 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Schneider-Thoma, J. et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet 399, 824–836 (2022).

    Article  CAS  PubMed  Google Scholar 

  9. Guinart, D. et al. Reasons for antipsychotic treatment switch: a systematic retrospective review of prescription records and prescriber notes. J. Clin. Psychiatry 83, 21m14272 (2022).

    Article  PubMed  Google Scholar 

  10. van Dee, V., Schnack, H. G. & Cahn, W. Systematic review and meta-analysis on predictors of prognosis in patients with schizophrenia spectrum disorders: an overview of current evidence and a call for prospective research and open access to datasets. Schizophr. Res. 254, 133–142 (2023).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada

    Marco Solmi

  2. Department of Mental Health, The Ottawa Hospital, Ottawa, Ontario, Canada

    Marco Solmi

  3. Ottawa Hospital Research Institute (OHRI), University of Ottawa, Ottawa, Ontario, Canada

    Marco Solmi

  4. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany

    Marco Solmi & Christoph U. Correll

  5. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

    Christoph U. Correll

  6. German Center for Mental Health (DZPG), Partner Site Berlin, Berlin, Germany

    Christoph U. Correll

Authors
  1. Marco Solmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph U. Correll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph U. Correll.

Ethics declarations

Competing interests

M.S. declares that he has received honoraria and/or has acted as a consultant for AbbVie, Angelini, Lundbeck and Otsuka. C.U.C. declares that he has acted as a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen and/or Johnson & Johnson, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, Pharmaceutical Product Development (PPD) Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Takeda, Teva, Tolmar, Vertex and Viatris, and has received grant support from Janssen and Takeda. C.U.C. also declares that he has provided expert testimony for Janssen and Otsuka and has served on data safety monitoring boards for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus and Teva. In addition, C.U.C. declares that he has received royalties from UpToDate and holds stock options for Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax and Quantic.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Solmi, M., Correll, C.U. Evidence-based clinical care and policy making for schizophrenia. Nat Rev Neurol 19, 643–644 (2023). https://doi.org/10.1038/s41582-023-00872-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-023-00872-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing